HYDROCHLOROTHIAZIDE 25 MG
HYDROCHLOROTHIAZIDE : 25 MG · DIN 02486962 · PRO DOC LIMITEE
Health Canada status: MARKETED
What is HYDROCHLOROTHIAZIDE?
HYDROCHLOROTHIAZIDE 25 MG contains HYDROCHLOROTHIAZIDE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02486962, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 14-Aug-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HYDROCHLOROTHIAZIDE used for?
Treatment of edema (associated with heart failure, hepatic cirrhosis, renal disease), hypertension (alone or adjunct), and toxemia of pregnancy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02486962 |
|---|---|
| Brand name | HYDROCHLOROTHIAZIDE |
| Generic / active ingredient | HYDROCHLOROTHIAZIDE : 25 MG |
| Manufacturer | PRO DOC LIMITEE |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C03AA03 HYDROCHLOROTHIAZIDE |
| AHFS class | 04:08.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 14-Aug-2019 |
| Original market date | 2020-02-06 00:00:00 |
How is it administered?
Adults: 50-100 mg once or twice daily for diuresis/hypertension. Infants/Children: 1.0 mg/lb body weight per day in two doses. Individualize dosage to smallest amount necessary.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at controlled room temperature (15°C to 30°C) away from heat and light.
How is it supplied?
25 mg: Bottles of 100 and 1000 tablets. 50 mg: Bottles of 100 tablets.
Contraindications
Anuria; severe progressive renal disease with increasing azotemia and oliguria; hypersensitivity to hydrochlorothiazide, sulfonamide-derived drugs, or any ingredient in the formulation.
Warnings and precautions
Risk of non-melanoma skin cancer; monitor electrolytes for imbalance (hypokalemia, hyponatremia); risk of acute myopia and secondary angle-closure glaucoma; potential for hyperuricemia.
What can be used instead?
Other Canadian products sharing ATC code C03AA03 HYDROCHLOROTHIAZIDE. 12 of 53 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-HYDROCHLOROTHIAZIDE | 12.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02327856 |
| APO-HYDROCHLOROTHIAZIDE | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 00326844 |
| APO-HYDROCHLOROTHIAZIDE | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 00312800 |
| HYDROCHLOROTHIAZIDE | 25 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02360594 |
| MINT-HYDROCHLOROTHIAZIDE | 12.5 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02425947 |
| MINT-HYDROCHLOROTHIAZIDE | 25 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02426196 |
| PMS-HYDROCHLOROTHIAZIDE | 12.5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02274086 |
| PMS-HYDROCHLOROTHIAZIDE | 25 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02247386 |
| PMS-HYDROCHLOROTHIAZIDE | 50 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02247387 |
| TEVA-HYDROCHLOROTHIAZIDE | 25 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00021474 |
Who else supplies HYDROCHLOROTHIAZIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HYDROCHLOROTHIAZIDE appears in 53 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.